150 related articles for article (PubMed ID: 37855069)
1. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
[TBL] [Abstract][Full Text] [Related]
2. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.
Tartaglione I; Origa R; Kattamis A; Pfeilstöcker M; Gunes S; Crowe S; Fagan N; Vincenzi B; Ruffo GB
Exp Hematol Oncol; 2020; 9():20. PubMed ID: 32793403
[TBL] [Abstract][Full Text] [Related]
3. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.
Viprakasit V; Hamdy MM; Hassab HMA; Sherief LM; Al-Bagshi M; Khattab M; Chuncharunee S; Dung PC; Küpesiz A; Shekhawat A; Sonawane Y; Perez LT; Slader C; Taher AT
Ann Hematol; 2023 Aug; 102(8):2039-2049. PubMed ID: 37227493
[TBL] [Abstract][Full Text] [Related]
4. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia.
Trachtenberg FL; Gerstenberger E; Xu Y; Mednick L; Sobota A; Ware H; Thompson AA; Neufeld EJ; Yamashita R;
Qual Life Res; 2014 Oct; 23(8):2277-88. PubMed ID: 24682717
[TBL] [Abstract][Full Text] [Related]
5. Advances in iron chelation therapy: transitioning to a new oral formulation.
Shah NR
Drugs Context; 2017; 6():212502. PubMed ID: 28706555
[TBL] [Abstract][Full Text] [Related]
6. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Taher AT; Origa R; Perrotta S; Kourakli A; Ruffo GB; Kattamis A; Goh AS; Cortoos A; Huang V; Weill M; Merino Herranz R; Porter JB
Am J Hematol; 2017 May; 92(5):420-428. PubMed ID: 28142202
[TBL] [Abstract][Full Text] [Related]
7. Jadenu
Yassin MA; Soliman AT; De Sanctis V; Hussein RM; Al-Okka R; Kassem N; Ghasoub R; Basha A; Nashwan AJ; Adel AM
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018064. PubMed ID: 30416696
[TBL] [Abstract][Full Text] [Related]
8. Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
Oyedeji CI; Crawford RD; Shah N
J Natl Med Assoc; 2021 Apr; 113(2):170-176. PubMed ID: 32892996
[TBL] [Abstract][Full Text] [Related]
9. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of a Dispersible Tablet of GPO-Deferasirox Monotherapy among Children with Transfusion-Dependent Thalassemia and Iron Overload.
Chuansumrit A; Songdej D; Sirachainan N; Kadegasem P; Saisawat P; Sungkarat W; Kempka K; Tungbubpha N
Hemoglobin; 2024 Jan; 48(1):47-55. PubMed ID: 38369714
[TBL] [Abstract][Full Text] [Related]
11. Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.
Horodniceanu EG; Bal V; Dhatt H; Carter JA; Huang V; Lasch K
Health Qual Life Outcomes; 2017 Jun; 15(1):129. PubMed ID: 28645270
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
Vichinsky E; El-Beshlawy A; Al Zoebie A; Kamdem A; Koussa S; Chotsampancharoen T; Bruederle A; Gilotti G; Han J; Elalfy M
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28296163
[TBL] [Abstract][Full Text] [Related]
13. Switching from dispersible to film coated tablet formulation of deferasirox improves hemoglobin levels and transfusional interval in patients with transfusion-dependent-thalassemia.
Quarta A; Sgherza N; Pasanisi A; Solfrizzi MP; Serra M; Vitucci A; Dello Iacono N; Renni R; Daprile C; Mosna F; Palma A; Frappampina R; Visceglie D; Pastore D
Br J Haematol; 2020 Apr; 189(2):e60-e63. PubMed ID: 32119115
[No Abstract] [Full Text] [Related]
14. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
16. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions.
Chalmers AW; Shammo JM
Ther Clin Risk Manag; 2016; 12():201-8. PubMed ID: 26929633
[TBL] [Abstract][Full Text] [Related]
18. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Cappellini MD; Porter J; El-Beshlawy A; Li CK; Seymour JF; Elalfy M; Gattermann N; Giraudier S; Lee JW; Chan LL; Lin KH; Rose C; Taher A; Thein SL; Viprakasit V; Habr D; Domokos G; Roubert B; Kattamis A;
Haematologica; 2010 Apr; 95(4):557-66. PubMed ID: 19951979
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
